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Abstract Incubating either Chinese hamster ovary (CHO) cells 
or 3T3-L1 adipocytes with insulin increased the phosphorylation 
of the eIF-4E-binding protein, PHAS-I. Insulin also activated 
p70S6K and the Erk-1 and Erk-2 isoforms of mitogen-activated 
protein kinase (MAP kinase). However, the concentrations of the 
hormone needed to activate MAP kinase were 10-100 times 
higher than those needed to increase PHAS-I phosphorylation 
and p70S 6 K activity. Incubating cells with the inhibitor of MAP 
kinase kinase (MEK) activation, PD 098059, blocked the effects 
of low concentrations of insulin on PHAS-I and p70S 6 K . The 
effects of the inhibitor were overcome by increasing concentra-
tions of insulin. The results indicate that insulin activates a 
P D 098059-sensitive kinase that is involved in the regulation of 
both p70S 6 K and PHAS-I. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Insulin rapidly stimulates protein synthesis by increasing 
the rate of m R N A translation [1,2]. This hormonal effect in-
volves phosphorylation of ribosomal proteins and translation 
factors, including the eIF-4E-binding protein, PHAS-I (also 
known as 4E-BP1) [3-5]. Non-phosphorylated PHAS-I binds 
tightly to eIF-4E, the m R N A cap-binding protein, and inhib-
its translation of capped m R N A both in vitro and in vivo 
[6,7]. When PHAS-I is phosphorylated in response to insulin, 
the PHAS-I/eIF-4E complex dissociates, thereby allowing e lF-
4E to participate in translation initiation [7-10]. 
PHAS-I is an excellent substrate for M A P kinase in vitro, 
and the kinase phosphorylates the protein in the same five 
sites that are phosphorylated when adipocytes are incubated 
with insulin [11,12]. However, neither the Erk-1 nor Erk-2 
isoforms of M A P kinase appears to be the major insulin-
stimulated PHAS-I kinase in cells. This conclusion is based 
in part on the finding that inhibiting M A P kinase activation 
with P D 098059 did not block PHAS-I phosphorylation in 
response to insulin in 3T3-L1 adipocytes or C H O cells 
[10,13]. P D 098059 is a specific inhibitor of the enzymes that 
activate M A P kinase [14], although 10 times higher concen-
trations of PD 098059 are required to inhibit M E K 2 than to 
inhibit M E K 1 [14]. Fur ther evidence of M A P kinase-inde-
pendent regulation of PHAS-I is provided by the findings 
that rapamycin promoted dephosphorylation of PHAS-I and 
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at tenuated the effect of insulin on phosphorylating the protein 
[10,15]. Rapamycin is a selective inhibitor of the function of 
m T O R , the mammalian homologue of the T O R l p and 
T O R 2 p proteins that have been implicated in translational 
control in Saccharomyces cerevisiae [16]. Rapamycin does 
not interfere with activation of M A P kinase, but it potently 
inhibits the insulin-stimulated phosphorylation and activation 
of p70S 6 K , a downstream element of the m T O R pathway [17-
21]. p70S 6 K itself does not phosphorylate PHAS-I [11]. Indeed, 
there is reason to suspect that PHAS-I and p70S 6 K proteins 
might be phosphorylated by the same proline-directed protein 
kinase, as all five phosphorylation sites in PHAS-I and the 
four sites in the 'SKAIPS ' domain of p70S 6 K have a Ser/Thr-
Pro motif [22]. 
The recent finding that P D 098059 promoted dephospho-
rylation of PHAS-I in non-stimulated C H O cells suggests that 
under some conditions the M A P kinase signaling pathway 
contributes to the control of PHAS-I [13]. In view of the 
similarities in the phosphorylation sites in PHAS-I and 
p70S 6 K , we decided to investigate the effects of P D 098059 
on the regulation of these two important proteins by insulin. 
2. Materials and methods 
2.1. Materials 
Porcine insulin (27 U/mg) was purchased from Eli Lilly. Antibodies 
to PHAS-I and p70S6k were generated as described previously [10,23]. 
PD 098059 was a gift from Alan Saltiel at Parke-Davis. [γ-32Ρ]ΑΤΡ 
was from DuPont NEN and rapamycin was obtained from Calbio-
chem. Most commonly used chemicals were from Sigma Chemical Co. 
Tissue culture reagents were purchased from Gibco BRL. 
2.2. Cell culture and treatment of cells 
3T3-L1 fibroblasts were cultured in Dulbecco's modified Eagle's 
medium containing 10% fetal calf serum (FCS) on plastic culture 
dishes (10 cm diameter), and converted to adipocytes by using differ-
entiation medium as described previously [10]. Experiments were per-
formed 10-14 days after withdrawal from differentiation medium. 
Prior to treatment, the growth medium was replaced with buffer con-
taining 0.5% bovine serum albumin (BSA) [10], and the cells were 
incubated for a total time of 3 h. Additions of PD 098059 and insulin 
were made at the appropriate times prior to the end of this incuba-
tion. To terminate the incubation, cells were washed twice in ice-cold 
phosphate-buffered saline and homogenized in 1 mM EDTA, 5 mM 
EGTA, 10 mM MgCl2, 2 mM dithiothreitol (DTT), 0.1 mM phenyl-
methylsulfonyl fluoride (PMSF), 10 μg/ml leupeptin, 10 μg/ml apro-
tinin, 1 mM benzamidine, 0.1 μΜ microcystin-LR, 10 mM KP¡, and 
50 mM ß-glycerophosphate (pH 7.4). 
Chinese hamster ovary cells expressing human insulin receptors 
(CHO-IR) were grown to confluency in alpha-minimal essential me-
dium containing nucleotides and 10% FCS as described previously 
[24], Cells were incubated in serum-free medium containing 0.5% 
BSA for 16 h, then incubated with hormone or drug for appropriate 
times. Incubations were terminated by removing the medium and 
freezing the cells with liquid nitrogen. Whole-cell lysates were pre-
pared by thawing cells in lysis buffer containing 20 mM HEPES 
(pH 7.4), 10 mM MgCl2, 2 mM EDTA, 10 mM sodium pyrophos-
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Fig. 1. Effect of rapamycin and PD 098059 on PHAS-I and p70S6K phosphorylation. Serum-starved CHO-IR cells were incubated at 37°C with-
out additions or with 25 nM rapamycin or 50 μΜ PD 098059 for 60 min, prior to adding increasing concentrations of insulin. Incubations 
were continued for 30 min. Samples were subjected to SDS-PAGE, before PHAS-I or p70S6K were detected by immunoblotting as described in 
Section 2. 
phate, 2 mM sodium orthovanadate, 1% Triton X-100, and the same 
protease and phosphatase inhibitors that were used to homogenize the 
adipocytes. 
2.3. Immunoprecipitations and electrophoretic analyses 
Extracts were prepared by centrifuging homogenates at 12000Xg 
for 20 min at 4°C. PHAS-I was analyzed as described previously [10]. 
p70S6K was immunoprecipitated by incubating samples (100 μΐ of ex-
tract) with antibody (4 μg) for 16 h at 4°C with constant mixing. 
Protein A-agarose beads (10 μΐ/sample), equilibrated in cell lysis buff-
er, were then added. After incubating for 2 h at 4°C, the beads were 
washed 4 times with lysis buffer without Triton X-100. 
Immunoprecipitated proteins were eluted using SDS sample buffer 
and subjected to SDS-PAGE [25] before proteins were electrophoreti-
cally transferred to polyvinylidene difluoride membrane (Millipore). 
For immunoblotting, membranes were incubated with antibodies 
(1 μg/ml) and washed as described previously [10]. Antibody binding 
was detected by enhanced chemiluminescence using alkaline phospha-
tase conjugated to goat anti-rabbit IgG. The intensities of the bands 
corresponding to PHAS-I or p70S6K were determined by two-dimen-
sional scanning using a laser densitometer (Molecular Dynamics Inc.). 
2.4. Protein kinase activities 
The activities of the Erk-1 and Erk-2 isoforms of MAP kinase were 
measured using [γ-32Ρ]ΑΤΡ and myelin basic protein as substrates in 
the gel renaturation method described by Wang and Erikson [26], or 
after immunoprecipitation as described previously [27]. The activity of 
p70S6K was measured in an immune complex assay by using intact 40S 
ribosomes as substrate essentially as described previously [23]. Briefly, 
protein A-agarose beads bound to immune complexes were incubated 
in a reaction mixture composed of 20 mM HEPES (pH 7.4), 100 mM 
ß-glycerophosphate, 3 mM EGTA, 0.2 mM sodium orthovanadate, 
2 mM DTT, 9 μΜ inhibitory peptide of cAMP-dependent protein 
kinase, 20 mM MgCl2, 10 μΜ calmidazolium, and 200 μΜ [γ-
32P]ATP ( ~ 5 000000 cpm) containing 35 μg/sample of 40S ribo-
somes. The reaction was terminated by adding SDS sample buffer. 
γ represent hyperphosphorylated forms of PHAS-I. Approx-
imately 25% of PHAS-I in non-stimulated CHO-IR cells was 
found in the non-phosphorylated a form. Insulin at concen-
3. Results 
3.1. Effect of PD 098059 and rapamycin on phosphorylation of 
PHAS-I and p70S6K in CHO-IR cells 
To investigate the effects of insulin on the phosphorylation 
state of PHAS-I , CHO- IR cells were incubated with increas-
ing concentrations of insulin before extracts were subjected to 
SDS-PAGE, followed by immunoblott ing to detect the 
PHAS-I protein. As observed with extracts of other cells 
and tissues, PHAS-I from non-stimulated CHO-IR cells was 
resolved into three bands, designated α, β and γ in order of 
decreasing electrophoretic mobility. These forms arise from 
differences in the phosphorylation state of the protein. In 
general phosphorylation decreases the mobility. Thus, β and 
Fig. 2. Effect of PD 098059 on MAP kinase and p70S6K activities. 
CHO-IR cells were incubated as in the legend to Fig. 1, except that 
for MAP kinase, cells were stimulated with insulin for only 10 min. 
This was done because MAP kinase activity peaks at 10 min, and 
then declines to a level near the control with prolonged incubation. 
A: MAP kinase activities in extracts were assessed by using an in-
gel assay with myelin basic protein as substrate. B: p70S6K activity 
was measured in an immune complex assay with 40S ribosomes as 
the substrate. Relative amounts of 32P incorporated into myelin ba-
sic protein and ribosomal protein S6 were determined by optical 
density scanning of autoradiograms. 
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Fig. 3. Effect of increasing concentrations of insulin in 3T3L-1 adipocytes. Cells were incubated with increasing concentrations of insulin for 
either 10 min for MAP kinase or 30 min for PHAS-1 and p70seK. A: Phosphorylation of PHAS-I was analysed in cell extracts by Western 
blotting. B: The activities of MAP kinase (■) and p70S6K ( ·) were determined as described in the legend to Fig. 2. 
trations as low as 1 μυ/ml decreased the amount of the a 
form, and increased the relative proportion of the more highly 
phosphorylated γ form (Fig. 1, top). As reported by Flynn 
and Proud [13] PD 098059 promoted the dephosphorylation 
of PHAS-I in non-stimulated CHO cells. The present results 
extend these earlier findings by demonstrating that PD 098059 
attenuated the effects of insulin on increasing PHAS-I phos-
phorylation. Indeed, at low concentrations of insulin, the 
magnitude of the effect of PD 098059 was comparable to 
that of rapamycin. 
As with PHAS-I, the insulin-induced phosphorylation of 
p70S6K can be monitored by the decreases in electrophoretic 
mobility. p70S6K from extracts of non-stimulated CHO-IR 
cells appeared as a single band of Mr = 70 000. Multiple forms 
of p70S6K having reduced electrophoretic mobility were ob-
served after incubating cells with insulin at concentrations 
as low as 0.01 mU/ml (Fig. 1, bottom), indicative of the 
phosphorylation and activation of the kinase by insulin. As 
expected, the effect of insulin was abolished by rapamycin 
(Fig. 1). Incubating the cells with PD 098059 before adding 
insulin also markedly decreased the hormonal effect on phos-
phorylation of p70S6K. 
3.2. Inhibition of MAP kinase and p70seK activities by the 
MEK inhibitor, PD 098059, in CHO-IR cells 
To investigate further the effects of PD 098059, CHO-IR 
cells were incubated with and without the MEK inhibitor in 
the presence of increasing concentrations of insulin before the 
activities of MAP kinase and p70S6K were measured. Little, 
if any, increase in MAP kinase activity was observed with 
10 μυ/ml insulin, even though p70S6K activity was increased 
by nearly 4-fold by this concentration of the hormone (Fig. 2). 
PD 098059 abolished the effects of the lower concentrations of 
insulin on increasing both MAP kinase (Fig. 2A) and p70S6K 
(Fig. 2B) activities. However, the effects of the inhibitor were 
overcome by increasing concentrations of insulin. The concen-
tration of PD 098059 (50 μΜ) required to inhibit the activa-
tion of p70S6K at low concentrations of insulin is within the 
concentration range that is known to abolish MEK [14]. 
3.3. Regulation of PHAS-I, MAP kinase andp70S6K in 3T3-L1 
adipocytes 
The effects of insulin and PD 098059 in 3T3-L1 adipocytes 
were similar to those observed in CHO-IR cells. In the adi-
pocytes concentrations of insulin as low as 1 μυ/ml increased 
the phosphorylation of PHAS-I (Fig. 3A). At this concentra-
tion of insulin, p70S6K activity was increased by over 3-fold. 
In contrast, MAP kinase activity was not significantly in-
creased until the insulin concentration reached 0.1 mU/ml 
(Fig. 3B). Thus, in 3T3-L1 adipocytes insulin was at least 
100-times more potent in increasing PHAS-I phosphorylation 
and p70S6K activity than in activating MAP kinase. 
3.4. Effect of PD 098059 on insulin-stimulated 3T3-L1 
adipocytes 
As in CHO-IR cells, PD 098059 promoted the dephospho-
rylation of PHAS-I, and attenuated the effects of low concen-
trations of insulin on increasing the phosphorylation of the 
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Fig. 4. Effect of PD 098059 on PHAS-I and p70S6K phosphorylation in 3T3-L1 adipocytes. Cells were incubated with rapamycin, PD 098059, 
and increasing concentrations of insulin as described in the legend to Fig. 1. Cell extracts were analyzed by Western blotting using antibodies 
to (A) PHAS-I or (B) p70S6K. 
protein (Fig. 4A). However, the effects of the MEK inhibitor 
were less pronounced in the adipocytes than in CHO-IR cells, 
and they were completely overcome when the insulin concen-
tration exceeded 0.01 mU/ml (Fig. 4A). Cells were incubated 
with PD 098059 for 1 h prior to the addition of insulin in the 
present study, but for only 20 min in previous experiments in 
3T3-L1 adipocytes. This difference, and the fact that high 
concentrations of insulin were used previously, explain why 
no effect of the inhibitor on PHAS-I was detected in our 
earlier study [10]. 
When assessed by gel-shift analysis, PD 098059 decreased 
the phosphorylation of p70S6K at even the highest concentra-
tion of insulin investigated in the 3T3-L1 adipocytes (Fig. 4B). 
However, increasing the hormone concentration overcame the 
inhibitory effect of PD 098059 on p70S6K activity. The most 
likely explanation for this apparent discrepancy is that with 
high insulin concentrations, the MEK inhibitor prevented 
phosphorylation of sites that affect the electrophoretic mobil-
ity but did not inhibit phosphorylation of sites most impor-
tant for activating the kinase. PD 098059 was more effective 
in preventing activation of MAP kinase than in inhibiting 
p70S6K (Fig. 5). In the presence of the inhibitor, the highest 
concentration of insulin tested elicited only a slight increase in 
the activities of Erk-1 and Erk-2. 
4. Discussion 
The finding that the MEK inhibitor, PD 098059, attenuates 
the effect of insulin on increasing the phosphorylation of 
PHAS-I would seem to indicate that the MAP kinase signal-
ing pathway is involved in the control of PHAS-I. However, 
this conclusion may be premature. The finding that with in-
creasing concentrations of insulin, the effect of the hormone 
on PHAS-I was maximal before Erk-1 or Erk-2 activities were 
even increased supports the view that neither of these isoforms 
of MAP kinase is the major mediator of insulin action on 
PHAS-I. Relatively low concentrations of insulin were needed 
to activate p70S6K, a downstream element of the mTOR-sig-
naling pathway. Moreover, PD 098059 decreased p70S6K 
phosphorylation and inhibited activation of the kinase by in-
sulin. Thus, the effects of PD 098059 are consistent with the 
increasing evidence that implicates the mTOR/p70S6K signal-
ing pathway in the control of PHAS-I phosphorylation. 
p70S6K is thought to be regulated independently of the 
MAP kinase signaling pathway, which is believed to be spe-
cifically inhibited by PD 098059 [14,28]. Regardless of the 
specificity of the inhibitor, the present findings indicate that 
inhibition of the p70S6K pathway must be considered as a 
potential explanation for effects observed with PD 098059 in 
the increasing number of studies in which the MEK inhibitor 
is being used to investigate the MAP kinase signaling path-
way. Previously, Alessi et al showed that PD 098059 does not 
directly inhibit p70S6K [14]. Unfortunately, the kinases respon-
sible for activating p70S6K are not known, so that it is not 
feasible to investigate the specificity of the inhibitor using 
these enzymes. Nevertheless, based on the present findings, 
we propose that in order to ascribe an effect of PD 098059 
to the MAP kinase pathway the effect should be shown to be 
resistant to rapamycin, which blocks p70S6K activation. 
PD 098059 appears to bind to a region of MEK-1 outside 
of the ATP-binding site, thereby blocking access to enzymes 
that activate the kinase [29]. It has been argued that because 
the compound does not bind to the highly conserved kinase 
domain, it is likely to be a more selective inhibitor than the 
class of kinase inhibitors that act competitively with ATP. 
Based on the defined specificity of the inhibitor, our findings 
suggest that MEK-1 and/or MEK-2 is involved in the activa-
tion of p70S6K by insulin. In view of their extremely restricted 
substrate specificity, it is unlikely that MEK-1 or MEK-2 
phosphorylate p70S6K. Erk-2 does not directly phosphorylate 
p70S6K in vitro [28]. Moreover, it is unlikely that inhibition of 
the Erk-1 and Erk-2 account for the effects on p70S6K, as the 
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Fig. 5. Effect of PD 098059 on MAP kinase and p70S6K activities in rat adipocytes. Cells were treated as in Fig. 4 except that for MAP kinase 
cells were stimulated with insulin for only 10 min. MAP kinase activity using an in-gel assay with myelin basic protein as substrate (A) or 
p70S6K activity was measured in an immune complex assay (B). 
effect of PD 098059 on p70S6K was observed under conditions 
in which the activities of these MAP kinase isoforms were not 
changed. Our findings are consistent with those of Lenormand 
et al. [30] who have shown that constitutively active MEK 
leads to activation of p70S6K, independently of MAP kinase, 
in a cell line which stably expresses ARaf 1 :ER, an estradiol-
regulated form of oncogenic Raf. Interestingly, Holt et al. [31] 
have presented evidence that the phosphorylation of mSOS is 
also regulated by insulin through a MEK-dependent and 
MAP kinase-independent pathway. 
p70S6K is regulated by the phosphorylation of two classes of 
Ser/Thr sites [reviewed in [32]]. In one class the phosphoryl-
ated residue is flanked by hydrophobic amino acids residues. 
The other class of sites has a Ser/Thr-Pro motif. As selectivity 
of protein kinases is often determined by the amino acids 
surrounding a Ser/Thr residue, it seems likely that p70S6K is 
controlled by multiple protein kinases. There is evidence that 
the enzyme is controlled by both phosphatidylinositol 3-ki-
nase-dependent and -independent pathways [33-35]. Our find-
ings suggest that a MEK-dependent, but Erk-independent, 
pathway participates in the control of p70S6K. It is interesting 
to speculate that this pathway leads to activation of a proline-
directed protein kinase that phosphorylates both p70S6K and 
PHAS-I. 
Acknowledgements: This work was supported in part by National In-
stitutes of Health Grants DK52753 and DK28312. 
References 
[1] S.R. Kimball, T.C. Vary, L.S. Jefferson, Annu. Rev. Physiol. 56 
(1994) 321-348. 
[2] R.M. O'Brien, D.K. Granner, Biochem. J. 278 (1991) 609-619. 
[3] R.M. Dentón, R.W. Brownsey, W.A. Hughes, G.J. Belsham, 
Diabetologia 18 (1980) 307-312. 
[4] P.J. Blackshear, R.A. Nemenoff, J. Avruch, Biochem. J. 204 
(1982) 817-824. 
[5] C. Hu, S. Pang, X. Kong, M. Velleca, J.C. Lawrence Jr., Proc. 
Nati. Acad. Sei. USA 91 (1994) 3730-3734. 
[6] T.-A. Lin, X. Kong, T.A.J. Haystead, A. Pause, G. Belsham, N. 
Sonenberg, J.C. Lawrence Jr., Science 266 (1994) 653-656. 
[7] A. Pause, G.J. Belsham, A.C. Gringas, O. Donze, T.-A. Lin, J.C. 
Lawrence Jr., N. Sonenberg, Nature 371 (1994) 762-767. 
[8] I. Azpiazu, A.R. Saltiel, A.A. DePaoli-Roach, J.C. Lawrence Jr., 
J. Biol. Chem. 271 (1996) 5033-5039. 
[9] S.R. Kimball, L.S. Jefferson, P. Fadden, T.A.J. Haystead, J.C. 
Lawrence Jr., Am. J. Physiol. 39 (1996) C705-C709. 
[10] T.-A. Lin, X. Kong, A.R. Saltiel, P.J. Blackshear, J.C. Lawrence 
Jr., J. Biol. Chem. 270 (1995) 18531-18538. 
[11] T.A.J. Haystead, C.M.M. Haystead, C. Hu, T.-A. Lin, J.C. Law-
rence Jr., J. Biol. Chem. 269 (1994) 23185-23191. 
[12] Fadden, P., Haystead, T.A.J. and Lawrence, J.C, Jr. (1997) 
J. Biol. Chem., in press. 
[13] A. Flynn, CG. Proud, FEBS Lett. 389 (1996) 162-166. 
[14] Alessi, D.R., Cuenda, A., Cohen, P., Dudley, D.T. and Saltiel, 
A.R. (1995) J. Biol. Chem. 270, 27489-27494. 
[15] L. Beretta, A.C. Gingras, Y.V. Svitkin, M.N. Hall, N. Sonen-
berg, EMBO J. 15 (1996) 658-664. 
[16] M.N. Hall, Biochem. Soc. Trans. 24 (1996) 234-239. 
[17] R.T. Abraham, G.J. Wiederrecht, Annu. Rev. Immunol. 14 
(1996) 483-510. 
176 P.H. Scott, J.C. Lawrence Jr.IFEBS Letters 409 (1997) 171-176 
[18] V. Calvo, C M . Crews, T.A. Vik, B.E. Bierer, Proc. Nati. Acad. 
Sei. USA 89 (1992) 7571-7575. 
[19] J. Chung, CJ . Kuo, G.R. Crabtree, J. Blenis, Cell 69 (1992) 
1227-1236. 
[20] CJ . Kuo, J. Chung, D.F. Florentino, W.M. Flanagan, J. Blenis, 
G. Crabtree, Nature 358 (1992) 70-73. 
[21] D J . Price, J.R. Grove, V. Calvo, J. Avruch, B.E. Bierer, Science 
257 (1992) 973-977. 
[22] S. Ferrari, W. Bannwarth, SJ. Morley, N.F. Totty, G. Thomas, 
Proc. Nati. Acad. Sei. USA 89 (1992) 7282-7286. 
[23] T.-A. Lin, J.C. Lawrence Jr., J. Biol. Chem. 269 (1994) 21255-
21261. 
[24] S.B. Waters, K. Yamauchi, J.E. Pessin, Mol. Cell. Biol. 15 (1995) 
2791-2799. 
[25] U.K. Laemmli, Nature 227 (1970) 680-685. 
[26] H.-C. Wang, R.L. Erikson, Mol. Biol. Cell 3 (1992) 1329-1337. 
[27] D. Chen, S.B. Waters, K.H. Holt, J.E. Pessin, J. Biol. Chem. 271 
(1996) 6328-6332. 
[28] L.M. Ballou, H. Luther, G. Thomas, Nature 349 (1991) 348-350. 
[29] D.T. Dudley, L. Pang, SJ. Decker, AJ . Bridges, A.R. Saltiel, 
Proc. Nati. Acad. Sei. USA 92 (1995) 7686-7689. 
[30] P. Lenormand, M. McMahon, J. Pouyssegur, J. Biol. Chem. 271 
(1996) 15762-15768. 
[31] K.H. Holt, B.G. Kasson, J.E. Pessin, Mol. Cell. Biol. 16 (1996) 
577-583. 
[32] S. Ferrari, G. Thomas, Crit. Rev. Biochem. Mol. Biol. 29 (1994) 
385^113. 
[33] X.-F. Ming, B.M. Burgering, S. Wennstrom, L. Claesson-Welsh, 
C.-H. Heldin, J.L. Bos, S.C Kozma, G. Thomas, Nature 371 
(1994) 426-429. 
[34] C Sutherland, R.M. O'Brien, D.K. Granner, J. Biol. Chem. 270 
(1995) 15501-15506. 
[35] K. Hara, K. Yonezawa, H. Sakaue, K. Kotani, A. Kojima, M.D. 
Waterfield, M. Kasuga, Biochem. Biophys. Res. Commun. 208 
(1995) 735-741. 
